Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to
University of Cambridge scientists have developed a first-time imaging technique that helps visualise and quantify the early triggers of Parkinson’s — the world’s
The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production
Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines
HQ Team September 30, 2025: Scientists from the Perelman School of Medicine at the University of Pennsylvania and Cincinnati Children’s have developed an
HQ Team September 27, 2025:Chronic disregards and systematic underinvestment has left women largely out of healthcare through the ages. What is more worrying
HQ Team September 26, 2025: Autism has long occupied a complex and often contentious place in medical and cultural history. Since it was
HQ Team September 25, 2025: Scientists in the United Kingdom have found a novel gene therapy known as AMT-130 that has slowed the